# International Flavors & Fragrances **Source:** https://geo.sig.ai/brands/international-flavors-fragrances **Vertical:** Manufacturing **Subcategory:** Enterprise **Tier:** Leader **Website:** iff.com **Last Updated:** 2026-04-14 ## Summary New York specialty ingredients (NYSE: IFF) at $11.48B 2024 net sales, EBITDA +16%; flavors/fragrances + N&B health/biosciences ($26B 2021 acquisition), 2025 guidance 1-4% growth competing with Givaudan and dsm-firmenich. ## Company Overview International Flavors & Fragrances Inc. (IFF) is a New York City, New York-based global specialty ingredients company — publicly traded on the New York Stock Exchange (NYSE: IFF) as an S&P 500 Materials component — creating and manufacturing flavors, fragrances, enzymes, probiotics, food ingredients, cosmetic actives, and pharmaceutical excipients for consumer goods companies, food manufacturers, beverage companies, and pharmaceutical firms through approximately 20,000 employees in 110 countries. In fiscal year 2024, IFF reported net sales of $11.48 billion and adjusted operating EBITDA growth of 16% to $2.21 billion, demonstrating improved profitability following the challenging integration of the DuPont Nutrition & Biosciences business (acquired 2021 for ~$26 billion in the largest transaction in IFF's history). For 2025, IFF guided 1-4% comparable currency-neutral sales growth, with continued margin improvement as the integration synergies are realized. CEO Jon Erik Fyrwald leads the company through its integration and portfolio optimization phase. IFF operates across four segments: Nourish (flavors, functional ingredients, proteins, food and beverage innovation), Scent (fine fragrances, consumer fragrances, cosmetic actives), Health & Biosciences (enzymes, microbiome, probiotics, animal nutrition), and Pharma Solutions (pharmaceutical excipients and delivery systems) — serving every major category of consumer products from food and beverages to personal care, household products, and medicine. IFF's specialty ingredients model creates value through proprietary formulation expertise that transforms commodity chemicals into value-added performance ingredients: when a consumer goods company reformulates a laundry detergent fragrance (to replace a synthetic musk discontinued for regulatory reasons), it does not replace "the fragrance" — it replaces a complex formula of 50-200 aroma chemicals blended to achieve a specific olfactory profile at a specific intensity under specific conditions (hot water release, dryness on fabric). IFF's fragrance chemists (perfumers) create the replacement formula using IFF's proprietary aromatic compounds, testing for regulatory compliance, wash performance, and olfactory alignment with the original — and the client cannot easily switch to a competitor because the formula, performance data, and regulatory documentation are specific to IFF's ingredient library. The Health & Biosciences segment's enzyme and probiotic ingredients similarly require years of customer formulation development and regulatory clearance before commercial use, creating high switching costs in biopharmaceutical, food ingredient, and animal nutrition applications. In 2025, IFF competes in global flavors and fragrances, specialty food ingredients, and health ingredients against Givaudan (SWX: GIVN, Swiss private-to-public flavor/fragrance leader, CHF 7.0B 2024 revenue), dsm-firmenich (AMS: DSFIR, Dutch-Swiss specialty nutrition and health, €12B revenue), and Symrise AG (ETR: SY1, German flavors/fragrances, €4.7B revenue) for consumer goods company ingredient supply agreements, new product formulation partnerships, and natural/clean-label ingredient innovation. The N&B integration (2021-2025) positioned IFF to offer food, beverage, and pharmaceutical customers a broader ingredient platform than either Givaudan or Symrise — combining fragrances with food ingredients, probiotics, and pharma excipients in a single supplier relationship. The 2025 strategy focuses on continued integration synergy realization, portfolio optimization through targeted divestitures of non-core businesses, debt reduction from the N&B acquisition leverage, and margin improvement toward peer-level EBITDA margins of 20%+. ## Frequently Asked Questions ### What does International Flavors & Fragrances (IFF) do? IFF is the world's largest specialty ingredients producer, creating products across taste, texture, scent, nutrition, enzymes, cultures, soy proteins, and probiotics. The company serves the food, beverage, health, household goods, personal care, and pharmaceutical industries with innovative ingredient solutions that elevate everyday products. ### Who are IFF's customers and target markets? IFF serves over 33,000 customers globally across multiple industries including food and beverage manufacturers, personal care and beauty brands, household products companies, pharmaceutical firms, and animal nutrition providers. Customers range from small regional producers to multinational consumer goods corporations. ### When was IFF founded? International Flavors & Fragrances was formed in 1958 through the merger of Polak & Schwarz (founded 1889 in the Netherlands) and van Ameringen-Haebler (founded 1918 in the United States). The company went public in 1961 and was listed on the New York Stock Exchange in 1964. ### Where is IFF headquartered and located? IFF is headquartered at 521 West 57th Street in New York City. The company operates globally with creative, sales, and manufacturing facilities in 44 countries, more than 110 manufacturing facilities, and over 100 R&D centers serving customers in 65+ countries worldwide. ### What is IFF's revenue and market position? IFF reported annual revenue of $11.48 billion in 2024 with a market capitalization of $16.77 billion. The company is the global leader in specialty ingredients, with dominant positions in flavors and fragrances (each ~25% of profits), and probiotics and enzymes through its Health & Biosciences segment (30% of profits). ### What makes IFF different from competitors? IFF differentiates through its unique combination of scientific expertise and creative artistry, comprehensive portfolio spanning flavors, fragrances, health, and food ingredients, and significant R&D investment of $671 million annually across 100+ research centers. The company's sustainability focus helped customers avoid 27.3 million metric tons of CO2 emissions in 2024—16.5 times its own manufacturing footprint. ### Who are IFF's main competitors? IFF competes with Givaudan, Firmenich (now part of DSM-Firmenich), Symrise, and Sensient Technologies in flavors and fragrances. In health and biosciences, competitors include Chr. Hansen, Kerry Group, and ADM. IFF's scale as the largest specialty ingredients producer and comprehensive portfolio provide competitive advantages. ### What major acquisitions has IFF completed? IFF's transformative acquisitions include Frutarom Industries for $7.1 billion in 2018, expanding natural ingredients capabilities, and the landmark 2021 merger with DuPont's Nutrition & Biosciences business valued at $26.2 billion, which brought expertise in probiotics, enzymes, and food protection. In 2024-2025, IFF sold its Pharma Solutions division to Roquette for $2.85 billion. ### How many employees does IFF have? IFF employs approximately 22,400 people globally across 65+ countries. The company maintains a diverse workforce with eight employee resource groups (colleague communities) and has been recognized with a score of 100 in diversity and inclusion rankings in 2024. ### Is IFF hiring? Yes, IFF regularly hires across various functions including research and development, sales, manufacturing, and corporate roles. Career opportunities can be found at www.iff.com/careers, with positions available across the company's 110+ manufacturing facilities and 100+ R&D centers globally. ### What's the latest news about IFF? Recent developments include Jon Erik Fyrwald becoming CEO in February 2024, the completion of the Pharma Solutions sale to Roquette for $2.85 billion in May 2025, and strong full-year 2024 results with adjusted operating EBITDA growing 16% to $2.21 billion. The company announced 2025 guidance of 1-4% comparable currency-neutral sales growth with strategic investments in R&D and capacity. ### What are IFF's future plans and strategic priorities? IFF's 2025 strategy focuses on organic growth across all business segments with 1-4% sales growth projected, strategic investments in R&D, commercial capabilities, capacity expansion, and technology platforms. Following the Pharma Solutions divestiture, the company is strengthening its balance sheet (net debt to EBITDA improved from 4.5x to 3.8x) and evaluating disciplined acquisitions to expand core capabilities in flavors, fragrances, and specialty ingredients. ## Tags b2b, manufacturing, public, global, enterprise --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*